Company Overview
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Why Investors Should Care
Revenue has grown at a 33.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.08.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $225.21M (+20.2% YoY); net profit $-15.70M.
- Trailing 12 Months Year-on-year growth — revenue +23.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 33.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 33.35% |
| 1 Year: | 23.10% |
Stock Price Performance
| 1 Year: | +157.86% |
| 6 Months: | -3.03% |
| 3 Months: | -7.49% |
| 1 Month: | -12.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.42 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 33.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 26.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AXGN Axogen, Inc. R2KR3KPHARMA | 38.06 | -56.81 | $2.23B | 0.00% | -3.96% | -18.21% | 33.35% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.42M | 8.15M | 8.11M | 10.38M | 11.21M | 11.41M | 12.24M | 15.17M | 16.05M | 16.97M | 17.26M | 20.58M | 22.66M | 23.43M | 23.29M | 26.70M | 28.56M | 28.16M | 24.26M | 22.12M | 33.43M | 32.49M | 31.04M | 33.58M | 31.20M | 31.01M | 34.45M | 36.96M | 36.66M | 38.16M | 41.27M | 41.38M | 47.91M | 48.64M | - | 56.66M | 60.08M | 59.90M | 61.46M | 69.73M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.64M | 14.09M | 15.49M | 15.27M | 19.06M |
| Gross Profit | 5.38M | 6.74M | 6.71M | 8.85M | 9.51M | 9.58M | 10.32M | 12.89M | 13.54M | 14.36M | 14.55M | 17.48M | 19.20M | 19.79M | 19.57M | 22.46M | 24.05M | 23.28M | 19.45M | 16.51M | 27.73M | 27.03M | 25.86M | 26.49M | 25.96M | 25.46M | 28.17M | 30.78M | 28.49M | 29.65M | 31.70M | 32.62M | 35.34M | 36.44M | - | 42.02M | 45.99M | 44.41M | 46.19M | 50.67M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.35M | 44.08M | 54.18M | 49.02M | 52.83M |
| Operating Income | -2.15M | -1.92M | -2.62M | -1.61M | -1.18M | - | -3.20M | -1.45M | -1.50M | - | -4.99M | -4.82M | -4.83M | - | -10.20M | -7.67M | -6.11M | - | -8.51M | -8.25M | -1.04M | - | -6.22M | -7.15M | -6.69M | -11.32M | -7.92M | -4.86M | -7.34M | -6.90M | -4.03M | -4.56M | -428.00K | -316.00K | - | 1.67M | 1.91M | -9.77M | -2.83M | -2.16M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.38M | 4.30M | -8.47M | -16.77M | 637.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.98M | 1.76M | 1.72M | 694.00K | 1.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 579.00K | 708.00K | -13.16M | -19.58M | -1.52M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.19M | -2.98M | -3.68M | -2.80M | -2.31M | -5.63M | -3.76M | -2.06M | -2.12M | -2.50M | -5.64M | -7.43M | -4.10M | -5.22M | -9.50M | -7.02M | -5.57M | -7.04M | -8.19M | -8.11M | -1.48M | -6.01M | -6.66M | -7.90M | -7.14M | -11.47M | -7.74M | -4.32M | -7.07M | -6.66M | -4.09M | -6.63M | -1.92M | -1.86M | - | 579.00K | 708.00K | -13.16M | -19.58M | -1.52M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.20 | -0.04 | - | -0.16 | -0.19 | -0.17 | -0.27 | -0.18 | -0.10 | -0.17 | -0.16 | -0.10 | -0.15 | -0.04 | -0.04 | - | 0.01 | 0.01 | -0.28 | -0.38 | -0.03 |
| R&D Expense | 736.40K | 936.01K | 978.34K | 936.82K | 1.12M | - | 1.41M | 1.52M | 1.80M | - | 2.06M | 2.60M | 3.31M | - | 4.14M | 4.28M | 4.18M | - | 4.61M | 4.07M | 4.23M | - | 5.75M | 5.72M | 6.40M | 6.28M | 7.02M | 7.05M | 6.33M | 7.14M | 6.69M | 7.41M | 6.66M | 7.00M | 6.09M | 6.85M | 7.57M | - | 7.52M | 8.59M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.00M | 4.85M | 7.69M | 10.95M | 16.82M | 27.33M | 41.11M | 60.43M | 83.94M | 106.71M | 112.30M | 127.36M | 138.58M | 159.01M | 187.34M | 225.21M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 29.77M | 37.14M | 45.36M | 57.85M |
| Gross Profit | 1.63M | 2.42M | 5.73M | 8.51M | 13.38M | 22.48M | 34.64M | 51.12M | 71.01M | 89.36M | 90.72M | 104.43M | 108.81M | 121.87M | 141.98M | 167.35M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 138.52M | 143.33M | 145.26M | 175.20M |
| Operating Income | -4.48M | -6.97M | -7.80M | -9.59M | -9.80M | -9.27M | -8.13M | -7.95M | -20.50M | -31.41M | -23.18M | -25.42M | -29.71M | -21.46M | -3.29M | -7.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -23.47M | -13.33M | 6.08M | 507.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 624.00K | 2.83M | 8.21M | 7.70M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -28.95M | -21.72M | -9.96M | -15.70M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.42M | -9.22M | -9.42M | -14.56M | -17.71M | -13.36M | -14.41M | -10.45M | -22.40M | -29.14M | -23.79M | -26.98M | -28.95M | -21.72M | -9.96M | -15.70M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.74 | -0.60 | -0.65 | -0.69 | -0.51 | -0.23 | -0.34 |
| R&D Expense | 436.01K | 697.36K | 1.43M | 2.13M | 3.03M | 3.24M | 4.21M | 6.70M | 11.77M | 17.51M | 17.85M | 24.18M | 25.63M | 27.34M | 27.77M | 32.88M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 6.41M | 12.50M | 20.23M | 27.68M | 16.40M | 36.70M | 46.36M | 58.88M | 160.17M | 154.64M | 201.38M | - | 195.39M | 196.83M | 203.73M | 221.69M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 98.08M | 88.00M | 99.22M | 120.42M |
| Cash & Equivalents | 282.80K | 1.80M | 8.19M | 13.91M | 20.07M | 8.22M | 25.91M | 30.01M | 36.51M | 24.29M | 35.72M | 48.77M | - | 15.28M | 31.02M | 27.55M | 35.55M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.91M | 23.02M | 33.18M | 42.37M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.19M | 25.15M | 24.11M | 26.17M |
| Total Liabilities | - | 18.11M | 6.42M | 23.06M | 27.55M | 27.65M | 28.50M | 31.44M | 33.69M | 13.19M | 22.49M | 78.23M | - | 94.39M | 101.16M | 99.82M | 92.84M |
| Current Liabilities | - | 9.39M | 2.02M | 1.48M | 2.10M | 2.45M | 3.71M | 11.08M | 13.72M | 13.04M | 20.88M | 22.83M | - | 23.75M | 30.43M | 30.61M | 23.56M |
| Long Term Debt | - | 0 | 4.40M | 21.58M | 25.36M | 25.09M | 24.70M | 20.27M | 19.81M | 35.00K | 0 | 32.03M | - | 45.71M | 46.60M | 47.50M | 48.39M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 67.43M | 69.29M | 68.69M | 67.63M |
| Total Equity | -28.64M | -27.11M | 6.07M | -2.83M | 136.63K | -11.25M | 8.20M | 14.92M | 25.18M | 146.98M | 132.15M | 123.15M | - | 101.00M | 95.67M | 103.91M | 128.85M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.45M | 43.12M | 44.15M | 47.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.94M | -7.08M | -8.66M | - | - | -13.05M | -11.24M | -9.24M | -17.86M | -19.87M | -9.63M | - | -16.07M | -5.72M | 4.54M | 812.00K |
| Investing Cash Flow | -72.00K | 7.11M | -127.28K | - | - | -555.52K | -1.16M | -1.29M | -98.19M | 27.27M | -16.96M | - | -3.20M | 19.25M | -10.30M | -5.32M |
| Financing Cash Flow | 5.53M | 6.36M | 14.51M | - | - | 31.30M | 16.50M | 17.02M | 109.84M | 4.03M | 40.47M | - | 1.79M | 1.95M | 2.29M | 10.50M |
| Capital Expenditure | - | -20.61K | -48.46K | -178.78K | -542.04K | -408.78K | -931.00K | -1.10M | -6.28M | -4.66M | -21.91M | - | -21.25M | -14.92M | -4.52M | -5.59M |
| Free Cash Flow | - | -7.10M | -8.71M | - | - | -13.46M | -12.17M | -10.34M | -24.14M | -24.54M | -31.53M | - | -37.32M | -20.63M | 11.00K | -4.78M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -17.47M | 15.49M | -3.47M | 5.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 54.1% | 50.0% | 74.5% | 77.7% | 79.5% | 82.3% | 84.3% | 84.6% | 84.6% | 83.7% | 80.8% | 82.0% | 78.5% | 76.6% | 75.8% | 74.3% |
| Operating Margin % | -149.2% | -143.7% | -101.4% | -87.6% | -58.3% | -33.9% | -19.8% | -13.2% | -24.4% | -29.4% | -20.6% | -20.0% | -21.4% | -13.5% | -1.8% | -3.5% |
| Net Margin % | -180.5% | -190.1% | -122.4% | -133.0% | -105.3% | -48.9% | -35.1% | -17.3% | -26.7% | -27.3% | -21.2% | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
| ROE % | 20.0% | -151.8% | 332.9% | -10,654.0% | 157.5% | -163.0% | -96.6% | -41.5% | -15.2% | -22.0% | -19.3% | - | -28.7% | -22.7% | -9.6% | -12.2% |
| ROCE % | 150.3% | -66.5% | -41.6% | -37.5% | -70.2% | -28.1% | -23.0% | -17.6% | -13.9% | -23.5% | -13.0% | - | -17.3% | -12.9% | -1.9% | -4.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.22% | 4.42M | $159.67M |
| 2 | Morgan Stanley | 5.11% | 2.75M | $99.28M |
| 3 | First Light Asset Management, LLC | 5.11% | 2.75M | $99.30M |
| 4 | Vanguard Capital Management LLC | 4.20% | 2.26M | $81.58M |
| 5 | Artemis Investment Management Llp | 3.31% | 1.78M | $64.35M |
| 6 | Polar Capital Holdings PLC | 2.79% | 1.50M | $54.22M |
| 7 | Wellington Management Group, LLP | 2.59% | 1.39M | $50.28M |
| 8 | Geode Capital Management, LLC | 2.56% | 1.38M | $49.69M |
| 9 | Citadel Advisors Llc | 2.53% | 1.36M | $49.17M |
| 10 | Wasatch Advisors LP | 2.41% | 1.30M | $46.82M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AXGN
Axogen, Inc. (AXGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE15cmVwWFZ0TWt1ZGYtcTVtb2hOVkZxZngxMVdvWmFTNllLX1dDZmltQmQzaTU3aXZwZk01X012anJBX24yYmExc3pkRTNNdkFObmc?oc=5" target="_blank">Axogen, Inc. (AXGN) Stock Price, News, Quote & History</…
Axogen, Inc. (AXGN) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1wdjhscmxqMVd3WGtJVjNEek43OTVIREwtNXphbWpvTGxJSk9nUzh2UUFoTHhJR2JKRjQzcjMyY2h0U0VyN0Jyc2hJaTVkUk1nM0E?oc=5" target="_blank">Axogen, Inc. (AXGN) stock price, news, quote and history…
Axogen, Stock Of The Day, Offers Entry After Bullish Rebound - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOWGNZbEtqY0JtTk9ZTjBfVkxxeDNFX09HaVN4V0YzcW1TSUJHdml4TFB4MHo0LVh0bGNlRGcwc2FhdFMxUHRNdUZiejY0UDMtbTlZUml5TVFOc3lhV1BERDg4Y2tWWmJpdE03dUdlVGlZanhkamFsZ3BwWWVfMkRzRzdZTmNHMW83RDdSTD…
AXGN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9yejNCcTJKSW91QXM0YkZfRzR2ajNEajVZMlVLUDJrbVhBWWFFT0FEWU5wN1l2YkZmRk1nSUpWVU4ycVFSQnFNakcwSFE3S0R4SmprSnRwR00zSFBGekZWNXItS2hPcDFoWmxUNDZLeG9FZmtTcTN3b1hR?oc=5" target="_blank">AXG…
Axogen (NasdaqCM:AXGN) Stock Forecast & Analyst Predictions - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1nWWdybFdFY2V1ZVo4aW1CYWZkc3Z3OWVGbEtBVTJCUzVYRGE5Qk5HZkFFV2EwTGp1Z1lQbmZBUHlGc2hheWNuVmJxaUpKek1BandsSmdkTjh0a2pmanhEMW5uT0EwWXpJckVDUkJDS19xeDZhVU40?oc=5" target="_blank">Axogen …
Axogen (NASDAQ:AXGN) Shares Slide After Q2 Earnings Miss Overshadows Revenue Beat and Raised Guidance - ChartMill
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNWE9vSndfYnh4Z2t4bFItZkM2eFpmampWR1VWT0dnRlhITVNVUmRaazI5aG5TU3NXYnlWSHlPZFQyWmdYS2ltMmRnb0x2Mk5wejdRYks2M19yaktIak1oQUVVVDNwSDJwRmZWM0VYaVdWT25Ca0txS09saGtMUTJrdXBqdl9BN1BSWTByRX…
AXGN — Frequently Asked Questions
What is the current share price of Axogen, Inc. (AXGN)?
As of 2026-10-23 16:27 PDT, Axogen, Inc. (AXGN) trades at $38.06 on NasdaqCM. Its 52-week range is $14.76 to $51.73.
What is the market capitalisation of AXGN?
Axogen, Inc. (AXGN) has a market capitalisation of $2.23B on NasdaqCM.
What is the P/E ratio of AXGN?
AXGN trades at a trailing price-to-earnings (P/E) ratio of -56.81. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 7.56.
What is the return on equity (ROE) of AXGN?
AXGN has a return on equity (ROE) of -18.21%. Its return on capital employed (ROCE) is -3.96%.
Is AXGN a good stock to buy?
This page provides a data-driven analysis of Axogen, Inc. (AXGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.